The stock of Inhibrx Inc. (NASDAQ:INBX) increased by $3.13 on Tuesday to at $22.48, up 16.18 percent. The last five days have seen an average of 551,736 shares of common stock traded. 6 times new highs were reached in the current year, with a fall of -$2.07. The average number of shares traded over the last 20 days was 427,099, while the average volume over the last 50 days totaled 369,106.
INBX stock appreciated 12.12% since last month. On 08/14/23, the company’s shares reached a one-month low of $15.01. The stock touched a high of $34.72 on 06/15/23, after rallying from a low of $12.60 in 52 weeks. The price of INBX stock has declined by -8.77% or -$2.07 this year, reaching a new high 6 times. Still, the stock price is down -35.25% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
INBX stock investors should be aware that Inhibrx Inc. (INBX) stock had its last reported insider trading activity 181 days ago on Mar 01. On Mar 01, Chief Scientific Officer Eckelman Brendan P. sold 40,000 shares at $24.21 each. This transaction resulted in the insider making $968,231. On Feb 28, Lappe Mark sold 60 shares at a price of US$25.02. After the transaction, the insider now owns 2,486,192 shares. Chief Scientific Officer Eckelman Brendan P. had earlier sold 11,250 shares on Feb 02 for $25.45 a share. The transaction was completed for $286,355.
Financial Health
For the three months ended June 29, Inhibrx Inc.’s quick ratio was 6.50, while its current ratio was 6.50, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $131.31 million and revenue of $2.19 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. INBX’s return on assets (ROA) during the last 12 months has been -74.70%. There was a -49.60% return on investment (ROI) in the past year.
Earnings Surprise
According to Inhibrx Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $30000.0, while revenues fell by -2266.67% to $20000.0. It was predicted that Inhibrx Inc.’s quarterly earnings would be -$1.08, but it ended up being -$1.03, beating the consensus by -4.90%. EBITDA was -$39.83 million for the quarter. At the end of Inhibrx Inc.’s most recent quarter ended June 29, its liabilities totaled 237.98 million, while its total debt was $208.61 million. Equity owned by shareholders amounts to $43.67 million.
Technical Picture
Here’s a quick look at Inhibrx Inc.’s (INBX) price momentum from a technical perspective. As of 28 August, the RSI 9-day stood at 71.86%, suggesting the stock is Overbought, with a 89.48% historical volatility rate.
The stochastic %K and %D were 84.03% and 75.08% respectively, while the average true range (ATR) was 1.54. Based on the 14-day stochastic reading of 95.33%, the RSI (14) reading is 62.67%. On the 9-day MACD Oscillator, the stock is at 1.11, and the 14-day reading is at 2.03.
Analyst Ratings
In its analyst report released on March 16, 2022, SMBC Nikko began covering Inhibrx Inc. (NASDAQ: INBX). The stock was rated as an Outperform by the brokerage firm. Analysts have assigned Inhibrx Inc. (INBX) an Buy rating. INBX is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 5 others recommend it as a buy.
What is INBX’s price target for the next 12 months?
The current consensus forecast for the stock is between $27.00 and $60.00, with a median target price of $46.00. In analyzing these forecasts, the average price target given by analysts for Inhibrx Inc. (INBX) is $46.60.
